About Aqemia
AQEMIA is a next-gen techbio generating one of the world's fastest-growing drug discovery pipelines. Our mission is to design fast many innovative drug candidates for critical diseases. Our differentiation lies in our unique quantum and statistical mechanics algorithms to power a generative artificial intelligence designing novel drug candidates, without the need to train on experimental data. We already delivered several drug discovery successes in the internal pipeline as well as in collaboration with Pharma companies - most advanced programs being currently in vivo optimization.
About the team you will join
As a Machine Learning Research Intern, you’ll join a team of engineers and researchers building algorithms to improve and accelerate our internal drug discovery pipeline. You will be working in the series-expansion team, composed of 3 ML engineers. On a day-to-day basis, you will interact with Victor Saillant.
Your role
You will explore the topic of molecular generation in depth and be responsible for literature review, implementation and training/evaluation of models on public and proprietary data.
Your internship should last between 4 and 6 months, and can start as early as possible in 2024.
Subject of the internship
The objective of the internship is to address the problem of molecule generation conditioned on a protein, and possibly in a constrained chemical space and additional physico-chemical properties. The proposed method involves the use of diffusion models on graphs to address this issue (see references [1][2]). Additionally, alternative approaches, like auto-regressive models, may be explored in a subsequent phase (see references [3][4]).
About us
We work for a mission: joining us means having your own impact on changing the way drugs are discovered, and helping to shape the direction of our fast-growing company and team.
🚀 Mission-Driven: We want to find many drugs and change drug discovery paradigm
💊 Fast-growing drug discovery pipe and proofs: Internal pipeline with multiple programs against cancer for now, most advanced ones currently in vivo proof of concept/ patent stage + Collaborations with several top Pharma companies such as Sanofi, J&J (...) incl. 140M$ deal with Sanofi
👥 Interdisciplinary world-Class team: built a team of 60 top tier people at the crossroads of tech and life sciences
👤 Experienced Founders: 15+ years experience including resp. leading research at ENS, Oxford, Cambridge and career in strategy con>sulting at BCG.
💫
DeepTech Innovators: Part of the French Tech 120 and France 2030, spinoff of Ecole Normale Superieure and CNRS🏢 Prime Location: Paris (1 Bd Pasteur) with 2 days of remote per week.
🌎 International environment: Our working language is English. We offer a relocation package for those who wish to join us in France, which includes assistance in finding an apartment, help with all administrative tasks, and optional French lessons.
💸 Fundraising: $60M with European tech/deeptech funds - Elaia Partners (French leader deeptech VC), Eurazeo (largest European investment fund), Bpifrance Large Venture (largest French fund and fund of funds) and Wendel (PE tech fund).